Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
9.58
+0.03 (0.31%)
At close: Aug 13, 2025, 4:00 PM
9.45
-0.13 (-1.36%)
After-hours: Aug 13, 2025, 6:38 PM EDT
Sagimet Biosciences Employees
Sagimet Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 4 or 40.00% compared to the previous year.
Employees
14
Change (1Y)
4
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$4,241,571
Market Cap
308.43M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14 | 4 | 40.00% |
Dec 31, 2023 | 10 | 0 | - |
Dec 31, 2022 | 10 | 3 | 42.86% |
Dec 31, 2020 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SGMT News
- 11 hours ago - Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 8 days ago - Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 2 months ago - Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - GlobeNewsWire
- 2 months ago - Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 - Seeking Alpha
- 2 months ago - Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis - GlobeNewsWire
- 2 months ago - Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025 - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 months ago - Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire